An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease

Trial Profile

An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Velaglucerase alfa (Primary)
  • Indications Gaucher's disease type I
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 30 May 2017 Planned End Date changed from 1 Sep 2019 to 31 Mar 2021.
    • 30 May 2017 Planned primary completion date changed from 1 Aug 2019 to 26 Feb 2021.
    • 19 Sep 2016 Planned End Date changed from 1 Aug 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top